4.5 Article

Current status of carbapenemases in Latin America

期刊

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 11, 期 7, 页码 657-667

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2013.811924

关键词

Acinetobacter baumannii; -lactamases; -lactams; carbapenemases; carbapenems; Enterobacteriaceae; Latin America; Pseudomonas aeruginosa; resistance

资金

  1. Merck Sharp Dohme
  2. Merck Colombia
  3. Janssen-Cilag SA
  4. Novartis
  5. Pfizer SA
  6. AstraZeneca Colombia SA
  7. Johnson Johnson
  8. Pfizer
  9. Merck
  10. BD
  11. AstraZeneca
  12. Novartis Inc
  13. Pfizer Inc.
  14. MSD Inc.
  15. sanofi-aventis Inc.
  16. United Medicals Brazil
  17. Merck Sharp Dhome

向作者/读者索取更多资源

Enterobacteriaceae and non fermenting Gram-negative bacilli have become a threat to public health, in part due to their resistance to multiple antibiotic classes, which ultimately have led to an increase in morbidity and mortality. -lactams are currently the mainstay for combating infections caused by these microorganisms, and -lactamases are the major mechanism of resistance to this class of antibiotics. Within the -lactamases, carbapenemases pose one of the gravest threats, as they compromise one of our most potent lines of defense, the carbapenems. Carbapenemases are being continuously identified worldwide; and in Latin America, numerous members of these enzymes have been reported. In this region, the high incidence of reports implies that carbapenemases have become a menace and that they are an issue that must be carefully studied and analyzed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据